UAB 1643- A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer


Awarded By

Total Award Amount

  • 86435.00
  • Direct Costs

  • 66489.00
  • Sponsor Award Id

  • Contributor

  • Erica Stringer-Reasor M.D.   Investigator  
  • Gabrielle Rocque M.D.   Investigator